Perfil
Lyda M.
Osorio is currently the Head-Pharmacology at IMED AB.
Prior to this, she worked as a Principal at Karolinska Institutet.
Cargos activos de Lyda M. Osorio
| Empresas | Cargo | Inicio |
|---|---|---|
IMED AB
 IMED AB Drugstore ChainsRetail Trade IMED AB is focused on the development and commercialization of fully human monoclonal antibodies for treatment of immune disorders and diseases such as ischemia/reperfusion injury, HIV and cancer. IMED’s unique antibodies modulate the natural process of cell death called apoptosis by selective and specific blocking or induction of central signaling pathways. IMED AB is a privately owned biotechnology company funded by Karolinska Development and LinkMed AB and intends to out-license its products to pharmaceutical companies. | Corporate Officer/Principal | 26/11/2009 |
Antiguos cargos conocidos de Lyda M. Osorio.
| Empresas | Cargo | Fin |
|---|---|---|
| Karolinska Institutet | Corporate Officer/Principal | - |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 1 |
|---|---|
IMED AB
IMED AB Drugstore ChainsRetail Trade IMED AB is focused on the development and commercialization of fully human monoclonal antibodies for treatment of immune disorders and diseases such as ischemia/reperfusion injury, HIV and cancer. IMED’s unique antibodies modulate the natural process of cell death called apoptosis by selective and specific blocking or induction of central signaling pathways. IMED AB is a privately owned biotechnology company funded by Karolinska Development and LinkMed AB and intends to out-license its products to pharmaceutical companies. | Retail Trade |
- Bolsa de valores
- Insiders
- Lyda M. Osorio
